{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:55:54Z","timestamp":1794333354282,"version":"4.9.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Odronextamab, a CD20\u00d7CD3 bispecific antibody, demonstrated robust efficacy and durable responses, with a generally manageable safety profile, in patients with relapsed\/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the phase 2 ELM-2 study. This exploratory analysis evaluated the prognostic value of minimal residual disease (MRD) status and tumor molecular profiles, based on circulating tumor DNA (ctDNA) analysis, for determining patient outcomes in ELM-2. Baseline and on-treatment ctDNA samples were used for MRD evaluation (AVENIO Oncology Assay Non-Hodgkin Lymphoma test); baseline ctDNA samples were also used for molecular profiling. At data cutoff (24 March 2025), the cycle 4, day 15 (C4D15) biomarker population with available ctDNA results comprised 60 patients with FL and 77 patients with DLBCL. Undetectable ctDNA at C4D15 was associated with prolonged progression-free survival (PFS) in the FL (hazard ratio [HR], 0.31; 95% confidence interval [CI], 0.14-0.67) and the DLBCL cohorts (HR, 0.42; 95% CI, 0.24-0.75). Combining undetectable ctDNA with achievement of positron emission tomography-computed tomography complete response at C4D15 was associated with extended PFS in both cohorts. Among patients with progressive disease per Lugano criteria, most had detectable ctDNA at C4D15 (FL, 15\/19; DLBCL, 28\/35). In the DLBCL cohort, LymphGen analysis by ctDNA showed that the MCD subtype trended toward shorter PFS, whereas the EZB subtype trended toward longer PFS, compared with the rest of the cohort. MRD by ctDNA may be prognostic of outcomes with odronextamab in FL and DLBCL and could form the basis of response-guided treatment paradigms. This trial is registered at www.ClinicalTrials.gov as #NCT03888105.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016332","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:00:02Z","timestamp":1756926002000},"page":"6130-6140","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Early clearance of circulating tumor DNA and association with odronextamab response in relapsed\/refractory FL and DLBCL"],"prefix":"10.1182","volume":"9","author":[{"given":"Jon E.","family":"Arnason","sequence":"first","affiliation":[{"name":"1Department of Medicine, Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3721","authenticated-orcid":false,"given":"Matthew","family":"Matasar","sequence":"additional","affiliation":[{"name":"2Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-2285","authenticated-orcid":false,"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[{"name":"3Hematology, Azienda Unit\u00e0 Sanitaria Locale-IRCCS, Reggio Emilia, Italy"},{"name":"4Surgical, Medical, Dental and Morphological Sciences Department, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0481-4111","authenticated-orcid":false,"given":"David","family":"Tucker","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Royal Cornwall Hospital, Truro, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5542-4383","authenticated-orcid":false,"given":"Dylan","family":"Sun","sequence":"additional","affiliation":[{"name":"6Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2579-0037","authenticated-orcid":false,"given":"Weiwei","family":"Tao","sequence":"additional","affiliation":[{"name":"6Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9419-6291","authenticated-orcid":false,"given":"Yuan O.","family":"Zhu","sequence":"additional","affiliation":[{"name":"6Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Kundu","sequence":"additional","affiliation":[{"name":"6Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4517-1546","authenticated-orcid":false,"given":"Namita T.","family":"Gupta","sequence":"additional","affiliation":[{"name":"6Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Leary","sequence":"additional","affiliation":[{"name":"6Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Jankovic","sequence":"additional","affiliation":[{"name":"6Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Ambati","sequence":"additional","affiliation":[{"name":"6Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Mohamed","sequence":"additional","affiliation":[{"name":"6Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aafia","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"6Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3839-6791","authenticated-orcid":false,"given":"Jurriaan","family":"Brouwer-Visser","sequence":"additional","affiliation":[{"name":"6Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"1","key":"2025120910262318400_bib1","doi-asserted-by":"crossref","first-page":"2321648","DOI":"10.1080\/2162402X.2024.2321648","article-title":"Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma","volume":"13","author":"Cassanello","year":"2024","journal-title":"Oncoimmunology"},{"key":"2025120910262318400_bib2","doi-asserted-by":"crossref","first-page":"17943","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Sci Rep"},{"issue":"4","key":"2025120910262318400_bib3","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/cts.13212","article-title":"Translational findings for odronextamab: from preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies","volume":"15","author":"Zhu","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"5","key":"2025120910262318400_bib4","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025120910262318400_bib5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: primary analysis of ELM-2","volume":"6","author":"Kim","year":"2025","journal-title":"Nat Cancer"},{"issue":"11","key":"2025120910262318400_bib6","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"key":"2025120910262318400_bib7","doi-asserted-by":"crossref","first-page":"107458","DOI":"10.1016\/j.pharmthera.2019.107458","article-title":"Circulating tumor DNA as an early cancer detection tool","volume":"207","author":"Campos-Carrillo","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"9","key":"2025120910262318400_bib8","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","article-title":"Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research","volume":"36","author":"Lauer","year":"2022","journal-title":"Leukemia"},{"issue":"28","key":"2025120910262318400_bib9","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"2025120910262318400_bib10","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1182\/bloodadvances.2022007706","article-title":"Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation","volume":"7","author":"Merryman","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2025120910262318400_bib11","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"12","key":"2025120910262318400_bib12","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025120910262318400_bib13","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1111\/cas.15996","article-title":"Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed\/refractory diffuse large B-cell lymphoma","volume":"114","author":"Izutsu","year":"2023","journal-title":"Cancer Sci"},{"issue":"8","key":"2025120910262318400_bib14","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"12","key":"2025120910262318400_bib15","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2025120910262318400_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1182\/blood-2023-178564","article-title":"Plasma circulating tumor DNA (ctDNA) as an alternative to tissue DNA for genotyping of DLBCL: results from the POLARIX study","volume":"142","author":"Jardin","year":"2023","journal-title":"Blood"},{"issue":"364","key":"2025120910262318400_bib17","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"7","key":"2025120910262318400_bib18","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/his.15168","article-title":"Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results","volume":"84","author":"Mata","year":"2024","journal-title":"Histopathology"},{"issue":"26","key":"2025120910262318400_bib19","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies","volume":"33","author":"Scott","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025120910262318400_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","article-title":"A randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA","volume":"13","author":"Sehn","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"15","key":"2025120910262318400_bib21","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2025120910262318400_bib22","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/ijc.30838","article-title":"TP53 mutation and survival in aggressive B cell lymphoma","volume":"141","author":"Zenz","year":"2017","journal-title":"Int J Cancer"},{"issue":"3","key":"2025120910262318400_bib23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41375-021-01444-6","article-title":"Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma","volume":"36","author":"Newman","year":"2022","journal-title":"Leukemia"},{"issue":"23","key":"2025120910262318400_bib24","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1182\/bloodadvances.2023011384","article-title":"TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era","volume":"7","author":"Landsburg","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2025120910262318400_bib25","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/10428194.2024.2301924","article-title":"NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL","volume":"65","author":"Tabari","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2025120910262318400_bib26","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"suppl 1","key":"2025120910262318400_bib27","doi-asserted-by":"crossref","first-page":"9257","DOI":"10.1182\/blood-2022-162814","article-title":"Detection of early molecular response (EMR) and minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL) using a validated next generation sequencing (NGS) assay for the detection of tumor variants in circulating tumor (ct)DNA","volume":"140","author":"Stokowski","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2025120910262318400_bib28","doi-asserted-by":"crossref","first-page":"e55895","DOI":"10.1371\/journal.pone.0055895","article-title":"A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphoma","volume":"8","author":"Care","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"2025120910262318400_bib29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"2025120910262318400_bib30","unstructured":"Sentieon Appnotes\n          . Somatic Variant Calling for SNPs and Indels. Accessed 2 May 2025. https:\/\/support.sentieon.com\/appnotes\/somatic\/."},{"issue":"12","key":"2025120910262318400_bib31","doi-asserted-by":"crossref","first-page":"giaa145","DOI":"10.1093\/gigascience\/giaa145","article-title":"Parliament2: accurate structural variant calling at scale","volume":"9","author":"Zarate","year":"2020","journal-title":"Gigascience"},{"issue":"4","key":"2025120910262318400_bib32","doi-asserted-by":"crossref","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLoS Comput Biol"},{"issue":"9","key":"2025120910262318400_bib33","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"2025120910262318400_bib34","unstructured":"National Cancer Institute\n          . Cancer Stat Facts: NHL \u2014 Diffuse Large B-Cell Lymphoma (DLBCL). Accessed 14 November 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html."},{"issue":"8","key":"2025120910262318400_bib35","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.mayocp.2015.04.025","article-title":"Non-Hodgkin lymphoma: diagnosis and treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"16","key":"2025120910262318400_bib36","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"27","key":"2025120910262318400_bib37","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025120910262318400_bib38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41375-019-0559-9","article-title":"MRD response in relapsed\/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial","volume":"34","author":"Pott","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2025120910262318400_bib39","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/bloodadvances.2021006415","article-title":"Risk profiling of patients with relapsed\/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA","volume":"6","author":"Herrera","year":"2022","journal-title":"Blood Adv"},{"issue":"27","key":"2025120910262318400_bib40","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025120910262318400_bib41","author":"Hou","year":"7-10  2024"},{"issue":"S1","key":"2025120910262318400_bib42","article-title":"Response in molecular subgroups and circulating tumor (ct)DNA kinetics in patients with relapsed and\/or refractory (R\/R) large B-cell lymphoma (LBCL) treated with glofitamab monotherapy","volume":"8","author":"Carlo-Stella","year":"2023","journal-title":"HemaSphere"},{"issue":"5","key":"2025120910262318400_bib43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025120910262318400_bib44","author":"Birhiray","year":"31   4  2024"},{"key":"2025120910262318400_bib45","author":"Hardin","year":"31   4  2024"},{"key":"2025120910262318400_bib46","author":"Matasar","year":"31   4  2024"},{"key":"2025120910262318400_bib47","author":"Chong","year":"31   4  2024"},{"key":"2025120910262318400_bib48","author":"Vitolo","year":"31   4  2024"},{"issue":"5","key":"2025120910262318400_bib49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/6130\/2443063\/blooda_adv-2025-016332-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/6130\/2443063\/blooda_adv-2025-016332-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:26:33Z","timestamp":1765293993000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/23\/6130\/547094\/Early-clearance-of-circulating-tumor-DNA-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":49,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016332","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,9]]},"published":{"date-parts":[[2025,12,1]]}}}